# EDGAR Filing Document

**Accession Number:** 0001801198
**File Stem:** 0001171843-25-003703
**Filing Date:** 2025-6
**Character Count:** 2967
**Document Hash:** 1e397670e8b9ad44eff3e0d504f6617a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-003703.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0001171843-25-003703

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250605

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Legend Biotech Corp
- **CENTRAL INDEX KEY:** 0001801198
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39307
- **FILM NUMBER:** 251025076

**BUSINESS ADDRESS:**
- **STREET 1:** 2101 COTTONTAIL LANE
- **CITY:** SOMERSET
- **STATE:** NJ
- **ZIP:** 08873
- **BUSINESS PHONE:** 732-850-5598

**MAIL ADDRESS:**
- **STREET 1:** 2101 COTTONTAIL LANE
- **CITY:** SOMERSET
- **STATE:** NJ
- **ZIP:** 08873

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 6-K**

**Report of Foreign Private Issuer** 

**Pursuant to Rule 13a-16 or 15d-16** 

**of the Securities Exchange Act of 1934** 

**Date of Report: June 5, 2025**

**Commission File Number: 001-39307** 

**Legend Biotech Corporation** 

**(Exact Name of Registrant as Specified in its Charter)** 

**2101 Cottontail Lane** 

**Somerset, New Jersey 08873** 

**(Address of principal executive office)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**Legend Biotech Appoints Peter Salovey, Ph.D., as Lead Independent Director**

On June 5, 2025, Legend Biotech Corporation (the "Company") announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, as Lead Independent Director, effective June 5, 2025.

Dr. Salovey has served as an independent director of the Company's Board of Directors since August 2024. He brings deep leadership experience and a track record of guiding organizations with integrity and vision through periods of strategic growth. In his new role, Dr. Salovey will serve as a key liaison among the Board of Directors, management, and shareholders.

This report on Form 6-K is hereby incorporated herein by reference in the registration statements of the Company on Form F-3 (Nos. 333-278050, 333-272222 and 333-257625) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **LEGEND BIOTECH CORPORATION** | **LEGEND BIOTECH CORPORATION** |
| By: | /s/ Ying Huang |
| Name: | Ying Huang, Ph.D. |
| Title: | Chief Executive Officer |

---